Hormonal therapies in migraine management: current perspectives on patient selection and risk management-Reference-Cited by-同舟云学术

Hormonal therapies in migraine management: current perspectives on patient selection and risk management

Published:2021-11-25 Issue:12 Volume:21 Page:1347-1355
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Bentivegna Enrico¹²^ORCID,Luciani Michelangelo¹²^ORCID,Scarso Francesco¹²,Bruscia Clara¹²,Chiappino Dario¹²,Amore Emanuele¹²,Nalli Gabriele¹²,Martelletti Paolo¹²^ORCID

Affiliation:

1. Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy

2. Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2021.2003706

Reference107 articles.

1. Advances in genetics of migraine

2. Gut-brain Axis and migraine headache: a comprehensive review

3. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system

4. Male and female sex hormones in primary headaches

5. Migraine start, course and features over the cycle of combined hormonal contraceptive users with menstrual migraine – temporal relation to bleeding and hormone withdrawal: a prospective diary-based study

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations for hormonal therapy in migraine patients: a critical review of current practice;Expert Review of Neurotherapeutics;2023-12-25

2. Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants;Headache: The Journal of Head and Face Pain;2023-05

3. Is now the time to reconsider risks, benefits, and limitations of estrogen preparations as a treatment for menstrually related migraine?;Expert Review of Neurotherapeutics;2023-04-03

4. New Migraine Drugs for Older Adults;Drugs & Aging;2023-02-24

5. BAY-117082-driven NLRP3 inflammasome inhibition resolves nitro-glycerine (NTG) neuronal damage in in vivo model of migraine;Biomedicine & Pharmacotherapy;2022-12